NIKKEI 225
38,639.32 -64.19 (-0.17%) HANG SENG
18,347.82 -128.98 (-0.70%) CRUDE OIL
75.74 +0.19 (+0.25%) GOLD FUTURES
2,398.30 +7.40 (+0.31%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,811.66 +409.50 (+0.74%)
Aura Biosciences, Inc. (AURA)
After hours:
| Previous close | 7.52 |
| Open | 7.46 |
| Bid | 7.40 x 100 |
| Ask | 7.49 x 200 |
| Day's range | 7.40 - 7.64 |
| 52-week range | 5.99 - 12.90 |
| Volume | |
| Avg. volume | 202,911 |
| Market cap | 370.088M |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET. The live webcast of the presentation will be available on the “Investors & Media” pa
- GlobeNewswire
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET. To register, click here. The event will feature Carol Shields, MD (Wills Eye Hospital), Hakan Demirci, MD (University of Michigan), and Mandeep Sagoo, MB, PhD, FRCS (
- GlobeNewswire
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, t
